Fulcrum Therapeutics (NASDAQ:FULC) Announces Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) posted its earnings results on Thursday. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.13), FiscalAI reports.

Fulcrum Therapeutics Stock Up 2.8%

FULC traded up $0.10 during trading on Thursday, reaching $3.72. The stock had a trading volume of 1,124,947 shares, compared to its average volume of 1,454,950. The stock has a 50 day moving average of $4.05 and a two-hundred day moving average of $6.95. The firm has a market capitalization of $247.86 million, a price-to-earnings ratio of -3.23 and a beta of 3.01. Fulcrum Therapeutics has a 1-year low of $2.83 and a 1-year high of $15.74.

Wall Street Analyst Weigh In

FULC has been the topic of a number of recent analyst reports. Truist Financial cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 price objective on Fulcrum Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th. Cantor Fitzgerald lowered Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, HC Wainwright lowered Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target on the stock. in a report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $8.20.

Insider Activity at Fulcrum Therapeutics

In other news, Director Alan Ezekowitz sold 18,000 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total value of $65,700.00. Following the sale, the director owned 10,927 shares of the company’s stock, valued at approximately $39,883.55. The trade was a 62.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in Fulcrum Therapeutics by 236.8% in the 4th quarter. Invesco Ltd. now owns 417,189 shares of the company’s stock valued at $4,718,000 after acquiring an additional 293,317 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $586,000. Ikarian Capital LLC lifted its stake in Fulcrum Therapeutics by 6.7% during the fourth quarter. Ikarian Capital LLC now owns 1,375,472 shares of the company’s stock valued at $15,557,000 after purchasing an additional 86,247 shares during the last quarter. Vestal Point Capital LP bought a new stake in Fulcrum Therapeutics during the fourth quarter worth approximately $10,744,000. Finally, Virtus Investment Advisers LLC bought a new stake in Fulcrum Therapeutics during the fourth quarter worth approximately $231,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.